The triple agonist also lowered HbA1C by up to 1.6% over 80 weeks, with up to 40% of participants reaching normal levels.
|Articles|July 25, 2013
Glycemic Targeting
Author(s)Peter Huckfeldt, PhD
In this video segment Dr. Huckfeldt discussed factors contributing to low levels of glycemic control. Patient, medication and physician factors can all effect medication adherence.
Advertisement
Glycemic control reduces the risks of complications in diabetes, but many patients with type 1 diabetes (T1D) still do not achieve their goals of glycemic control, said Dr. Peter Huckfeldt, PhD, Prodessor, Pardee RAND Graduate School. In this video segment Dr. Huckfeldt discussed factors contributing to low levels of glycemic control. Patient, medication and physician factors can all effect medication adherence.
Advertisement
Related to this article
AASM urges CMS to reject proposed 2027 Medicare conversion factor cuts of 1.19% to 1.68% and revise sleep testing and remote monitoring policies.
A rare case of soft-tissue sarcoma spreading to the heart shows how multimodal imaging guided diagnosis and care in a 36-year-old man.
A meta-analysis of 22 studies found steatotic liver disease in about three-quarters of patients with sleep-disordered breathing.
FDA accepted United Therapeutics' sNDA for inhaled treprostinil in IPF. Here's what it could mean for patient access, coverage, and costs
Sustainable models require asking what a result shows, what design produced it, and whether the design was built to measure value or just produce a number.
CAR T-cell therapy must be treated as a complete "vein-to-vein" episode, with community practices needing to take control of cases for a period of time.
Weekend catch-up sleep was associated with lower odds of overactive bladder and milder symptoms, with the benefit concentrated in the first 1.5 hours.
Advertisement
Advertisement
Trending on AJMC
1
IRA, 340B, Medicaid: The Policy Pressures on Community Oncology
2
Drug Price Drives Value of MASH Therapies More Than Efficacy
3
Retatrutide Yields Up to 20.8% Weight Loss in Obesity With T2D
4
Vibegron Outranks Mirabegron, Tolterodine on Several OAB Measures
5